{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma+of+the+Breast&page=23",
    "query": {
      "condition": "Carcinoma of the Breast",
      "page": 23
    },
    "page_size": 10
  },
  "pagination": {
    "page": 23,
    "page_size": 10,
    "total_count": 6983,
    "total_pages": 699,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma+of+the+Breast&page=24&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma+of+the+Breast&page=22&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-16T16:45:19.952Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05933265",
      "title": "Study of LP-184 in Patients With Advanced Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Metastatic Solid Tumor",
        "GBM",
        "TNBC - Triple-Negative Breast Cancer",
        "NSCLC",
        "Pancreatic Adenocarcinoma",
        "DDR Gene Mutation"
      ],
      "interventions": [
        {
          "name": "LP-184",
          "type": "DRUG"
        },
        {
          "name": "Olaparib",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab & Ipilimumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lantern Pharma Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 64,
      "start_date": "2023-06-09",
      "completion_date": "2026-07-28",
      "has_results": false,
      "last_update_posted_date": "2026-05-04",
      "last_synced_at": "2026-10-16T16:45:19.952Z",
      "location_count": 7,
      "location_summary": "Springdale, Arkansas • Indianapolis, Indiana • Louisville, Kentucky + 4 more",
      "locations": [
        {
          "city": "Springdale",
          "state": "Arkansas"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05933265"
    },
    {
      "nct_id": "NCT01148407",
      "title": "Platelet Modulation: A Study of Angiogenic and Coagulation Proteins in Patients With Cancer",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cancer"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Vermont",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2010-06",
      "completion_date": "2013-08",
      "has_results": false,
      "last_update_posted_date": "2011-04-22",
      "last_synced_at": "2026-10-16T16:45:19.952Z",
      "location_count": 1,
      "location_summary": "Burlington, Vermont",
      "locations": [
        {
          "city": "Burlington",
          "state": "Vermont"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01148407"
    },
    {
      "nct_id": "NCT04033419",
      "title": "Memantine for Prevention of Cognitive Decline in Patients With Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cognitive Decline",
        "Chemo-brain"
      ],
      "interventions": [
        {
          "name": "Memantine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "UNC Lineberger Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 55,
      "start_date": "2019-09-25",
      "completion_date": "2022-04-04",
      "has_results": true,
      "last_update_posted_date": "2023-04-20",
      "last_synced_at": "2026-10-16T16:45:19.952Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04033419"
    },
    {
      "nct_id": "NCT04209465",
      "title": "A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor"
      ],
      "interventions": [
        {
          "name": "BDTX-189",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Black Diamond Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 91,
      "start_date": "2019-12-19",
      "completion_date": "2022-09-16",
      "has_results": true,
      "last_update_posted_date": "2025-04-17",
      "last_synced_at": "2026-10-16T16:45:19.952Z",
      "location_count": 24,
      "location_summary": "Scottsdale, Arizona • Long Beach, California • Orange, California + 20 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Lake Mary",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04209465"
    },
    {
      "nct_id": "NCT05035836",
      "title": "A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "HER2-positive"
      ],
      "interventions": [
        {
          "name": "Zanidatamab",
          "type": "DRUG"
        },
        {
          "name": "Letrozole",
          "type": "DRUG"
        },
        {
          "name": "Tamoxifen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 20,
      "start_date": "2021-11-16",
      "completion_date": "2028-12-29",
      "has_results": false,
      "last_update_posted_date": "2026-08-24",
      "last_synced_at": "2026-10-16T16:45:19.952Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05035836"
    },
    {
      "nct_id": "NCT01257932",
      "title": "Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using Diffuse Optical Spectroscopic Imaging",
      "overall_status": "WITHDRAWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Diffuse Optical Spectroscopy Imaging",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "University of California, Irvine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 0,
      "start_date": "2010-12",
      "completion_date": "2013-10",
      "has_results": false,
      "last_update_posted_date": "2022-11-01",
      "last_synced_at": "2026-10-16T16:45:19.952Z",
      "location_count": 1,
      "location_summary": "Irvine, California",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01257932"
    },
    {
      "nct_id": "NCT01791998",
      "title": "Magnetic Resonance Thermal Image Guided Laser Interstitial Thermal Therapy in Treating Patients With Breast Cancer",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Ductal Breast Carcinoma in Situ",
        "Invasive Ductal Breast Carcinoma",
        "Stage IA Breast Cancer",
        "Stage IB Breast Cancer"
      ],
      "interventions": [
        {
          "name": "magnetic resonance thermal imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "laser interstitial thermal therapy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "Female only"
      },
      "enrollment_count": 0,
      "start_date": "2012-08",
      "completion_date": "2014-06",
      "has_results": false,
      "last_update_posted_date": "2014-10-15",
      "last_synced_at": "2026-10-16T16:45:19.952Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01791998"
    },
    {
      "nct_id": "NCT03344965",
      "title": "Olaparib In Metastatic Breast Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Breast Cancer",
        "Invasive Breast Cancer",
        "Somatic Mutation Breast Cancer (BRCA1)",
        "Somatic Mutation Breast Cancer (BRCA2)",
        "CHEK2 Gene Mutation",
        "ATM Gene Mutation",
        "PALB2 Gene Mutation",
        "RAD51 Gene Mutation",
        "BRIP1 Gene Mutation",
        "NBN Gene Mutation"
      ],
      "interventions": [
        {
          "name": "Olaparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Beth Israel Deaconess Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 114,
      "start_date": "2018-04-01",
      "completion_date": "2026-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-01-05",
      "last_synced_at": "2026-10-16T16:45:19.952Z",
      "location_count": 20,
      "location_summary": "Birmingham, Alabama • San Francisco, California • Chicago, Illinois + 15 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03344965"
    },
    {
      "nct_id": "NCT05864144",
      "title": "A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumor, Adult",
        "Advanced Solid Tumor",
        "Head and Neck Cancer",
        "Breast Cancer",
        "Colon Cancer",
        "Pancreatic Cancer",
        "Gastric Cancer",
        "Esophageal Cancer",
        "Prostate Cancer",
        "Uterine Cancer",
        "Cervix Cancer",
        "Ovarian Cancer",
        "Kidney Cancer",
        "Bladder Cancer",
        "Thyroid Cancer",
        "Melanoma",
        "Sarcoma",
        "Advanced Cancer",
        "Metastatic Cancer",
        "Refractory Cancer",
        "Non Small Cell Lung Cancer",
        "Merkel Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "SNS-101 (anti-VISTA)",
          "type": "DRUG"
        },
        {
          "name": "Cemiplimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sensei Biotherapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 98,
      "start_date": "2023-05-31",
      "completion_date": "2026-06-02",
      "has_results": false,
      "last_update_posted_date": "2026-09-02",
      "last_synced_at": "2026-10-16T16:45:19.952Z",
      "location_count": 10,
      "location_summary": "Los Angeles, California • Aurora, Colorado • Louisville, Kentucky + 7 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05864144"
    },
    {
      "nct_id": "NCT00028964",
      "title": "Combination Chemotherapy After Surgery With or Without Chinese Herbal Therapy to Treat Symptoms in Women With Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Drug/Agent Toxicity by Tissue/Organ"
      ],
      "interventions": [
        {
          "name": "Chinese herbs",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "doxorubicin hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "adjuvant therapy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": null,
      "start_date": "2001-02",
      "completion_date": "2005-02",
      "has_results": false,
      "last_update_posted_date": "2011-02-23",
      "last_synced_at": "2026-10-16T16:45:19.952Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00028964"
    }
  ]
}